RNA 표적 소분자 신약 개발 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 적응증별, 최종사용자별, 지역별＆경쟁(2021-2031년)

The Global RNA Targeting Small Molecule Drug Discovery Market is projected to expand significantly, growing from USD 1.95 Billion in 2025 to USD 6.47 Billion by 2031, at a Compound Annual Growth Rate (CAGR) of 22.13%. This market primarily focuses on identifying and developing small molecular weight compounds that directly bind to complex RNA structures like bulges, loops, and pseudoknots to influence their biological functions. These small molecules offer distinct advantages over alternative RNA-based therapies, such as antisense oligonucleotides or siRNAs, including the potential for oral bioavailability, enhanced tissue distribution, and the ability to penetrate the blood-brain barrier. Key drivers for this growth include the urgent need to address previously

Market Driver

A primary force accelerating the Global RNA Targeting Small Molecule Drug Discovery Market is the sharp increase in strategic pharmaceutical partnerships and venture capital investments. Major companies are seeking to diversify their therapeutic pipelines beyond traditional protein targets, increasingly validating this modality by securing access to proprietary platforms capable of modulating RNA function in conditions such as neurodegenerative diseases and oncology. An illustrative example of this trend is Wayfinder Biosciences' collaboration with Daiichi Sankyo in April 2025, which aims to leverage Wayfinder's RNA-targeting small molecule platform for neurodegeneration, underscoring the industry's reliance on external innovation.

Concurrently, the escalating global prevalence of cancer and rare genetic disorders is driving demand for novel therapeutic agents that can address

Market Challenge

A critical barrier impeding the growth of the Global RNA Targeting Small Molecule Drug Discovery Market is the inherent difficulty in achieving sufficient selectivity, largely due to RNA's significant structural plasticity and electrostatic nature. This complexity often leads to promiscuous interactions with abundant cellular RNAs, such as ribosomes, thereby elevating the risk of off-target toxicity. Consequently, developers face increased attrition rates during preclinical development, necessitating substantial investment in extensive validation studies. This prolongs development timelines and raises the financial threshold for market entry, ultimately deterring risk-averse capital allocation.

This elevated technical risk profile has a direct, negative impact on the investment climate for nascent companies endeavoring to translate discovery platforms into clinical assets. The pervasive uncertainty regarding safety profiles curtails the crucial funding required for these innovative modalities. For instance, in the second quarter of 2025, start-up financings across the gene, cell, and RNA therapy sector only garnered $197 million, continuing a trend of declining deal volume and value over the preceding three quarters, as reported by the American Society of Gene & Cell Therapy (ASGCT). This capital constriction, driven by the high technical demands of ensuring selectivity, directly limits the progression of viable candidates into the market.

Market Trends

The advancement of small molecule splicing modulators represents a significant market trend, facilitating the correction of pre-mRNA processing defects in genetic diseases that were previously considered untreatable. By specifically binding to splice sites, these compounds can precisely promote the inclusion or exclusion of particular exons, thereby restoring the production of functional proteins. This approach offers a powerful alternative to more complex gene therapies. This therapeutic promise was recently validated by Skyhawk Therapeutics, which reported in September 2025 positive interim results from its Phase 1 clinical trial of SKY-0515, demonstrating a 62% reduction of mutant huntingtin protein in Huntington's disease patients and proving the modality's ability to engage challenging central nervous system targets.

Simultaneously, the expanding research and development focus on Non-Coding RNA (ncRNA) targets is unlocking a vast and previously unexplored segment of the transcriptome, extending beyond traditional protein-coding genes. Developers are increasingly leveraging precision therapies to target long non-coding RNAs (lncRNAs), which are known to play crucial regulatory roles in various cellular states and disease progression, particularly within fibrosis and oncology. Growing investor confidence in this non-coding sector is evident; HAYA Therapeutics, for example, secured $65 million in Series A funding in May 2025 to advance its lead lncRNA-targeting candidate, HTX-001, into clinical trials for heart failure, underscoring the industry's commitment to developing drugs for the regulatory genome.

Key Market Players

• Accent Therapeutics, Inc.
• Anima Biotech Inc.
• Arrakis Therapeutics, Inc.
• AstraZeneca Plc
• Epics Therapeutics, Inc.
• Expansion Therapeutics, Inc.
• F. Hoffmann-La Roche AG
• H3 Biomedicine Inc.
• PTC Therapeutics, Inc.
• Ribometrix, Inc.

Report Scope

In this report, the Global RNA Targeting Small Molecule Drug Discovery Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

RNA Targeting Small Molecule Drug Discovery Market, By Indication

• Cancer
• Infectious Diseases
• Metabolic Diseases
• Neurological Diseases
• Others

RNA Targeting Small Molecule Drug Discovery Market, By End Users

• Pharmaceutical and Biopharmaceutical Companies
• Academic and Research Institutes
• Others

RNA Targeting Small Molecule Drug Discovery Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global RNA Targeting Small Molecule Drug Discovery Market.

Available Customizations:

Global RNA Targeting Small Molecule Drug Discovery Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global RNA Targeting Small Molecule Drug Discovery Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
  • 5.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America RNA Targeting Small Molecule Drug Discovery Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication
  • 6.2.2. By End Users
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By End Users
  • 6.3.2. Canada RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By End Users
  • 6.3.3. Mexico RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By End Users

7. Europe RNA Targeting Small Molecule Drug Discovery Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By End Users
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By End Users
  • 7.3.2. France RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By End Users
  • 7.3.3. United Kingdom RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By End Users
  • 7.3.4. Italy RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By End Users
  • 7.3.5. Spain RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By End Users

8. Asia Pacific RNA Targeting Small Molecule Drug Discovery Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By End Users
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By End Users
  • 8.3.2. India RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By End Users
  • 8.3.3. Japan RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By End Users
  • 8.3.4. South Korea RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indication
      • 8.3.4.2.2. By End Users
  • 8.3.5. Australia RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indication
      • 8.3.5.2.2. By End Users

9. Middle East & Africa RNA Targeting Small Molecule Drug Discovery Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By End Users
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By End Users
  • 9.3.2. UAE RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By End Users
  • 9.3.3. South Africa RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By End Users

10. South America RNA Targeting Small Molecule Drug Discovery Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By End Users
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By End Users
  • 10.3.2. Colombia RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By End Users
  • 10.3.3. Argentina RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By End Users

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global RNA Targeting Small Molecule Drug Discovery Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Accent Therapeutics, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Anima Biotech Inc.
• 15.3. Arrakis Therapeutics, Inc.
• 15.4. AstraZeneca Plc
• 15.5. Epics Therapeutics, Inc.
• 15.6. Expansion Therapeutics, Inc.
• 15.7. F. Hoffmann-La Roche AG
• 15.8. H3 Biomedicine Inc.
• 15.9. PTC Therapeutics, Inc.
• 15.10. Ribometrix, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer